Sanofi Targets Counterfeit Viagra Market With OTC Cialis
This article is for subscribers only.
Sanofi sees an attractive opportunity in the rampant market for counterfeit Viagra: luring men away from dodgy online pharmacies with an over-the-counter version of a competing erection drug.
The French drugmaker plans safety and efficacy studies to support an application to produce a non-prescription version of Eli Lilly & Co.’s Cialis. One selling point is to provide a legal and effective alternative to fake copies of Pfizer Inc.’s Viagra and other drugs, said Vincent Warnery, senior vice president of global consumer health care at Sanofi.